Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Investments (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Long-Term Investments for 5 consecutive years, with $80.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 44.37% to $80.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.0 million through Dec 2025, down 44.37% year-over-year, with the annual reading at $80.0 million for FY2025, 44.37% down from the prior year.
  • Long-Term Investments hit $80.0 million in Q4 2025 for BridgeBio Pharma, down from $92.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $160.4 million in Q3 2024 to a low of $60.7 million in Q2 2021.
  • Historically, Long-Term Investments has averaged $108.0 million across 3 years, with a median of $108.0 million in 2025.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 254.17% in 2021 and later crashed 44.37% in 2025.
  • Year by year, Long-Term Investments stood at $60.7 million in 2021, then skyrocketed by 136.86% to $143.7 million in 2024, then plummeted by 44.37% to $80.0 million in 2025.
  • Business Quant data shows Long-Term Investments for BBIO at $80.0 million in Q4 2025, $92.2 million in Q3 2025, and $108.0 million in Q2 2025.